ADC Therapeutics SA Statistics
Share Statistics
ADC Therapeutics SA has 96.69M shares outstanding. The number of shares has increased by 19.9% in one year.
Shares Outstanding | 96.69M |
Shares Change (YoY) | n/a |
Shares Change (QoQ) | 0.48% |
Owned by Institutions (%) | n/a |
Shares Floating | 77.83M |
Failed to Deliver (FTD) Shares | 883 |
FTD / Avg. Volume | 0.12% |
Short Selling Information
The latest short interest is 3.17M, so 3.28% of the outstanding shares have been sold short.
Short Interest | 3.17M |
Short % of Shares Out | 3.28% |
Short % of Float | 4.07% |
Short Ratio (days to cover) | 9.62 |
Valuation Ratios
The PE ratio is -0.57 and the forward PE ratio is -1.97.
PE Ratio | -0.57 |
Forward PE | -1.97 |
PS Ratio | 1.95 |
Forward PS | 2.2 |
PB Ratio | -0.91 |
P/FCF Ratio | -1.11 |
PEG Ratio | n/a |
Enterprise Valuation
ADC Therapeutics SA has an Enterprise Value (EV) of -18.58M.
EV / Earnings | 0.08 |
EV / Sales | -0.27 |
EV / EBITDA | 0.13 |
EV / EBIT | 0.11 |
EV / FCF | 0.15 |
Financial Position
The company has a current ratio of 4.97, with a Debt / Equity ratio of -0.77.
Current Ratio | 4.97 |
Quick Ratio | 4.73 |
Debt / Equity | -0.77 |
Total Debt / Capitalization | -335.36 |
Cash Flow / Debt | -1.04 |
Interest Coverage | -3.58 |
Financial Efficiency
Return on equity (ROE) is 1.62% and return on capital (ROIC) is 834.46%.
Return on Equity (ROE) | 1.62% |
Return on Assets (ROA) | -0.68% |
Return on Capital (ROIC) | 834.46% |
Revenue Per Employee | 254.79K |
Profits Per Employee | -879.32K |
Employee Count | 273 |
Asset Turnover | 0.2 |
Inventory Turnover | 0.16 |
Taxes
Income Tax | 39.11M |
Effective Tax Rate | -0.2 |
Stock Price Statistics
The stock price has increased by 17.61% in the last 52 weeks. The beta is 1.6, so ADC Therapeutics SA's price volatility has been higher than the market average.
Beta | 1.6 |
52-Week Price Change | 17.61% |
50-Day Moving Average | 2.74 |
200-Day Moving Average | 3.45 |
Relative Strength Index (RSI) | 42 |
Average Volume (20 Days) | 709.55K |
Income Statement
In the last 12 months, ADC Therapeutics SA had revenue of $69.56M and earned -$240.05M in profits. Earnings per share was $-2.94.
Revenue | 69.56M |
Gross Profit | 67.03M |
Operating Income | -165.99M |
Net Income | -240.05M |
EBITDA | -146.76M |
EBIT | -165.99M |
Earnings Per Share (EPS) | -2.94 |
Balance Sheet
The company has $278.60M in cash and $124.38M in debt, giving a net cash position of $154.22M.
Cash & Cash Equivalents | 278.60M |
Total Debt | 124.38M |
Net Cash | 154.22M |
Retained Earnings | -1.34B |
Total Assets | 349.08M |
Working Capital | 265.33M |
Cash Flow
In the last 12 months, operating cash flow was -$118.69M and capital expenditures -$3.22M, giving a free cash flow of -$121.90M.
Operating Cash Flow | -118.69M |
Capital Expenditures | -3.22M |
Free Cash Flow | -121.90M |
FCF Per Share | -1.49 |
Margins
Gross margin is 96.36%, with operating and profit margins of -238.63% and -345.11%.
Gross Margin | 96.36% |
Operating Margin | -238.63% |
Pretax Margin | -280.94% |
Profit Margin | -345.11% |
EBITDA Margin | -210.99% |
EBIT Margin | -238.63% |
FCF Margin | -175.25% |
Dividends & Yields
ADCT does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Payout Ratio | n/a |
Earnings Yield | -157.22% |
FCF Yield | -67.42% |
Analyst Forecast
The average price target for ADCT is $8, which is 327.8% higher than the current price. The consensus rating is "Buy".
Price Target | $8 |
Price Target Difference | 327.8% |
Analyst Consensus | Buy |
Analyst Count | 5 |
Scores
Altman Z-Score | -5.62 |
Piotroski F-Score | 2 |